Wu Mianhua

Prof. Wu Mianhua


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
YJYi Ji
Yi Ji
LLLi Li
Li Li
WLWenting Li
Wenting Li
LLLiu Li
Liu Li
YMYanxia Ma
Yanxia Ma
WMWu Mianhua
Wu Mianhua
The Xiaoai Jiedu recipe (XJR) is a traditional Chinese medicine formulation used in clinical settings to treat liver cancer. It has shown promising effectiveness by combining herbal and animal-derived ingredients, offering a new approach to cancer treatment. However, its mechanism of action is poorly understood. The molecular processes underlying the inhibitory effects of the XJR on hepatocellular cancer (HCC) were investigated. The primary chemical components of XJR and associated disease targets relevant to HCC were anticipated and compiled using a database. The potential targets and processes by which XJR influenced HCC were investigated using GO and KEGG enrichment analyses, as well as protein-protein interaction (PPI) networks. Transmission electron microscopy, laser confocal microscopy, and Western blotting were used to evaluate autophagy, while CCK-8 assays measured cell viability and Western blotting and flow cytometry evaluated apoptosis. In vivo assays were conducted employing an HCC xenograft mouse model. Network pharmacology analysis identified 456 intersecting targets between XJR and HCC. The top five active components are quercetin, cholesterol, jaceosidine, eupafolin, and oleanolic acid. The key targets include TP53, AKT1, IL6, EGFR, SRC, HSP90AA1, TNF, IL1B, MYC, and CASP3. Additionally, the autophagy pathway was found to be one of the main pathways through which XJR intervenes in HCC. The increased quantity of autophagosomes and autolysosomes, the overexpression of Beclin1 and LC3A/B-II proteins, and the downregulation of P62 all suggest that XJR stimulated autophagy in HCC cells. Functional tests employing pathway-specific activators and inhibitors and siRNA-based knockdown demonstrated that XJR promoted autophagy by blocking AKT/mTOR signaling. Furthermore, XJR reduced the viability of HCC cells and promoted apoptosis by upregulating apoptosis proteins. Autophagy inhibitors and Beclin1 silencing reversed these effects. Research conducted in vivo showed that XJR activated autophagy through the AKT/mTOR axis, thereby markedly reducing tumor growth and inducing tumor cell demise. These studies show that XJR activates autophagy in both cellular and animal models to induce apoptosis and decrease HCC cell proliferation, as shown by network pharmacology and verification assays. Further, these findings provide experimental evidence that the anti-tumor activity of XJR involves autophagy stimulation.

1 January 2025 in Human Mutation
Verified
Journal Article
Open access
YQYuanyuan Qin
Yuanyuan Qin
HZHongli Zhou
Hongli Zhou
LZLingyan Zhu
Lingyan Zhu
WLWenting Li
Wenting Li
ZJZequn Jiang
Zequn Jiang
WMWu Mianhua
Wu Mianhua
Background: Microsatellite instability (MSI) serves as a crucial biomarker for immune checkpoint blockade therapy in colorectal cancer (CRC). However, only around 40% of MSI CRC patients benefit from ICB. Investigating the mechanisms underlying MSI CRC, particularly its association with cell death and the immune microenvironment, can provide insights to improve immunotherapy efficacy.Methods: Transcriptomic and clinical data of MSI CRC patients were collected from TCGA and GEO databases. Differential expression analysis, weighted gene coexpression network analysis, and Cox regression models were employed to identify five cell death–related prognostic genes (POU4F1, AIF1L, SLC18A1, INSL4, and HOXC6). Single‐cell analysis, immune infiltration analysis, and in vitro and in vivo experiments were conducted to validate their roles in MSI CRC.Results: The five‐gene risk model effectively stratified high‐ and low‐risk groups and predicted survival differences (AUC > 0.6). AIF1L exhibited elevated expression in MSI‐H groups and demonstrated a significant correlation with ferroptosis and immune cell infiltration. In vitro experiments showed that AIF1L boosted cell proliferation and migration via modulating ferroptosis, showing correspondence with in vivo experiments. Moreover, enrichment analysis revealed that AIF1L participated in immune‐related signaling pathways, potentially impacting the tumor microenvironment and patient prognosis.Conclusion: AIF1L may regulate MSI CRC progression by promoting ferroptosis, serving as a prospective biomarker for prognosis and a therapeutic target for personalized therapy. This study uncovers new mechanisms in MSI CRC and provides a foundation for optimizing immunotherapy, though further investigation into its specific roles is needed.

14 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
QGQianrong Guo
Qianrong Guo
YSYan Sun
Yan Sun
YNYue Ni
Yue Ni
WLWenting Li
Wenting Li
LWLixin Wang
Lixin Wang
WMWu Mianhua
Wu Mianhua
Purpose: This study aimed to evaluate the association between pre-radiotherapy cachexia and treatment discontinuation, as well as other treatment-related outcomes, in patients with head and neck squamous cell carcinoma (HNSCC) receiving definitive radiotherapy. Methods: This single-center retrospective cohort study consecutively enrolled M0 HNSCC patients who received definitive radiotherapy between July 2023 and December 2025. Cachexia was defined using an operational approach based on core diagnostic variables available in the medical records, informed by the Asian Working Group for Cachexia (AWGC) 2023 criteria. The primary outcome was treatment discontinuation. Secondary outcomes included unplanned radiotherapy interruptions, treatment-related adverse events, timing of acute radiation toxicity, timing of acute myelosuppression, nutritional risk during radiotherapy, and blood transfusion requirements. Logistic regression analyses were performed to assess the association between cachexia and treatment discontinuation. Results: A total of 137 patients were included, of whom 72 (52.6%) were classified as having cachexia. Treatment discontinuation was significantly higher in the cachexia group compared to the non-cachexia group (25.0% vs. 4.6%; P<0.001), and the incidence of treatment-related adverse events was also higher (97.2% vs. 78.5%; P<0.001). The distribution of first documented acute radiation toxicity across fraction-based categories differed between groups (P = 0.037). No significant differences were observed in unplanned interruptions, timing of acute myelosuppression, nutritional risk, or transfusion requirements. In univariable logistic regression, cachexia was significantly associated with treatment discontinuation (OR = 6.89; 95% CI 1.92–24.67; P = 0.003). After adjustment for age, Eastern Cooperative Oncology Group (ECOG) performance status, and concurrent chemotherapy, cachexia remained significantly associated with treatment discontinuation (OR = 6.05; 95% CI, 1.63–22.49; P = 0.007). Sensitivity analysis using Firth’s penalized logistic regression yielded consistent results. Conclusions: In M0 HNSCC patients receiving definitive radiotherapy, pre-radiotherapy cachexia is significantly associated with treatment discontinuation and is accompanied by a higher incidence of treatment-related adverse events. Assessment of cachexia prior to radiotherapy may provide clinically relevant information on treatment tolerance and help identify patients at high risk of therapy discontinuation.

27 May 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YJYi Ji
Yi Ji
WLWenting Li
Wenting Li
LLLiu Li
Liu Li
YMYanxia Ma
Yanxia Ma
QLQingfeng Li
Qingfeng Li
WMWu Mianhua
Wu Mianhua

27 October 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YWYuan-Yuan Wu
Yuan-Yuan Wu
YWYuanyuan Wu
Yuanyuan Wu
ZLZi-Yu Lu
Zi-Yu Lu
ZTZhuo-Hui Tang
Zhuo-Hui Tang
WLWen-Ting Li
Wen-Ting Li
WMWu Mianhua
Wu Mianhua
Background: The Xiaoai Jiedu recipe (XJR), a traditional Chinese medicinal formula, has been applied clinically for liver cancer management. XJR exhibits promising anti-tumor potential and may offer a novel strategy for oncological intervention. This study was designed to investigate the molecular mechanisms by which XJR exerts its pharmacological effects against hepatocellular carcinoma (HCC). Methods: In vivo assays were conducted employing an HCC xenograft mouse model, and HepG2 cells were employed in vitro . ELISA, immunohistochemistry (IHC), immunofluorescence (IF), RT-PCR and western blot were performed to detect PTEN-induced putative kinase 1 (PINK1)-mediated mitophagy and NLRP3 (NOD-like receptor protein 3) inflammasome activation. The cellular mitochondrial reactive oxygen species (ROS) levels were tested with DCFH-DA and MitoSOX. Transmission electron microscopy (TEM) and JC-1 were utilized to observe the mitochondrial morphology and function, as well as mitochondrial membrane potential (MMP) in the process of XJR intervention for HCC. Results: XJR prominently promoted pyroptosis by upregulating the related inflammatory cytokines levels in serum and HepG2 cells. The key targets include PINK1, parkin, p62, LC3B, TOMM20, COX IV, NLRP3, ASC, GSDMD, caspase1, IL-1β and IL-18 were observed. XJR disrupted PINK1-mediated mitophagy, which in turn increased mitochondrial ROS levels and promoted NLRP3 inflammasome assembly both in vitro and in vivo . Meanwhile, functional assays using pathway-specific inhibitors and siRNA-mediated knockdown further demonstrated that XJR suppresses mitophagy and enhances NLRP3 inflammasome activation via inhibition of the PINK1/parkin signaling pathway. Conclusions: The preliminary results of the present study suggested that XJR may alleviate PINK1-mediated mitophagy and motivate NLRP3 signaling pathway to subsequently exert anti-tumor effects in HCC.

16 September 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YQYuanyuan Qin
Yuanyuan Qin
JLJing Li
Jing Li
YQYifan Qiu
Yifan Qiu
JCJianming Chang
Jianming Chang
LLLi Li
Li Li
CMCui Mao
Cui Mao
Background: Acute radiation enteritis (ARE) is a common complication of abdominal or pelvic radiotherapy characterized by inflammatory activation and epithelial barrier dysfunction. However, the molecular mechanisms underlying ARE remain incompletely understood. This study investigated transcriptomic alterations associated with ARE and evaluated the protective effects of Qing Hua Yi Chang Formula (QHYCF). Methods: A murine model of ARE was established using abdominal irradiation followed by QHYCF treatment. Histopathological analysis, TUNEL staining, RT-qPCR, western blotting, and ELISA were performed to assess intestinal injury and inflammatory responses. Transcriptomic profiling combined with bioinformatic analyses was used to identify inflammatory signatures and pathways associated with ARE. Results: QHYCF attenuated radiation-induced intestinal injury, particularly at the medium dose. Transcriptomic analysis revealed dysregulation of immune- and inflammation-related pathways after irradiation and identified NLRP3-associated inflammatory signaling as a prominent inflammatory alteration in ARE. QHYCF treatment was associated with reduced NLRP3 expression and decreased serum levels of IFN-γ, IL-1β, and IL-18. In addition, QHYCF partially restored Claudin-1 expression, suggesting improvement in epithelial barrier integrity. Conclusion: ARE progression is closely associated with inflammatory activation and epithelial barrier disruption. NLRP3-associated inflammatory alterations and Claudin-1 changes may represent molecular features associated with radiation-induced intestinal injury. QHYCF was associated with attenuation of inflammatory responses and preservation of epithelial barrier integrity.